Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions: ABF-101, Placebo; Drug
Lead sponsor: Aptabio Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: HIV, HIV Infections
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 15
States / cities: Tuscon, Arizona • Atherton, California • Culver City, California + 12 more

Conditions: Venous Stasis Ulcers
Interventions: Fish Oil; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ezogabine, Placebo; Drug
Lead sponsor: Brian Wainger; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more

Conditions: Obesity, Induction of Labor Affected Fetus / Newborn
Interventions: Cefazolin, Placebo, Azithromycin; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine 80 MG; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: AZD6793, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more

Conditions: Adrenoleukodystrophy
Interventions: Leriglitazone, Placebo; Drug
Lead sponsor: Minoryx Therapeutics, S.L.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Stanford, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Celiac Disease
Interventions: Latiglutenase, Placebo; Drug · Other
Lead sponsor: Immunogenics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, Exenatide LAR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more

Conditions: Healthy Volunteers
Interventions: SXC-2023, Placebo; Drug
Lead sponsor: Promentis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Stress Disorder
Interventions: Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo; Drug · Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 10 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Inflammatory Response
Interventions: Digoxin, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: JBT-101 (lenabasum), Placebo; Drug · Other
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 8 more

Conditions: Type 1 Diabetes
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cocaine Dependence
Interventions: oxytocin, saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Inflammation; Skin
Interventions: Turmeric tablets, Curcumin and Bioperine tablets, Placebo tablets; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Rhinitis, Allergic, Perennial
Interventions: Fluticasone furoate nasal spray, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more

Conditions: Chronic Pain
Interventions: Tramadol HCl ER; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Duncansville, Pennsylvania

Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions: DEN4 Vaccine Candidate, DEN4 Vaccine Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 80
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Search by objective public record fields.

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

Atomoxetine in Veterans With Comorbid ADHD/PTSD

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients

Latiglutenase as a Treatment for Celiac Disease

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Guanfacine Extended Release and Mindfulness Skills Therapy

Inhibition of Sterile Inflammation by Digoxin

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals

Turmeric and Curcumin on Sebum Production

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis